Kyverna Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Kyverna Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- KYTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001994702
Board of directors
- Since 2024
-
Brian L. Kotzin · DirectorSince 2024
-
Christi Shaw · DirectorSince 2024
- Since 2024
- Since 2024
- Since 2024
-
Mert Aktar · DirectorSince 2024
-
Peter Maag · Director · Chief Executive OfficerSince 2024
-
Stephen Constantine Liapis · DirectorSince 2024
-
Warner Weston Biddle · Director · Chief Executive OfficerSince 2024
Chief executives
Warner Weston Biddle
· Chief Executive Officer
Since September 2024
Peter Maag
· Chief Executive Officer
2024 – 2024
· Former
Board connections
7 of this board's directors also sit on 19 other boards.
- via Fred E. Cohen and Peter Maag
- via Beth C. Seidenberg and Fred E. Cohen
- via Beth C. Seidenberg
- via Christi Shaw
- via Christi Shaw
- via Ian T. Clark
- via Ian T. Clark
- via Ian T. Clark
- via Fred E. Cohen
- via Daniel K. Spiegelman
- via Daniel K. Spiegelman
- via Ian T. Clark
- via Brian L. Kotzin
- via Beth C. Seidenberg
- via Daniel K. Spiegelman
- via Ian T. Clark
- via Fred E. Cohen
- via Beth C. Seidenberg
- via Daniel K. Spiegelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 6, 2024 | Walker Karen Marie Officer (Chief Technology Officer) | Option exercise | +9,636 | $4.42 | $42,591 |
| May 28, 2024 | Jones Ryan Alexander Officer (Chief Financial Officer) | Option exercise | +10,870 | $0.73 | $7,935 |
| May 28, 2024 | Jones Ryan Alexander Officer (Chief Financial Officer) | Option exercise | +7,146 | $0.73 | $5,217 |
| Feb 12, 2024 | Vida Ventures GP III, L.L.C. 10% owner | Derivative conversion | +4,523,924 | — | — |
| Feb 12, 2024 | Fred E. Cohen Director, 10% owner | Derivative conversion | +4,523,924 | — | — |
| Feb 12, 2024 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +3,787,940 | — | — |
| Feb 12, 2024 | Westlake BioPartners GP I, LLC 10% owner | Derivative conversion | +3,787,940 | — | — |
| Feb 12, 2024 | Bain Capital Life Sciences Fund III, L.P. 10% owner | Derivative conversion | +2,713,868 | — | — |
| Feb 12, 2024 | GILEAD SCIENCES, INC. 10% owner | Derivative conversion | +3,216,119 | — | — |
| Feb 12, 2024 | Northpond Ventures III GP, LLC Former 10% Owner | Derivative conversion | +2,805,426 | — | — |
| Feb 12, 2024 | Vida Ventures GP III, L.L.C. 10% owner | Open-market purchase | +252,553 | $22.00 | $5,556,166 |
| Feb 12, 2024 | Beth C. Seidenberg Director, 10% owner | Derivative conversion | +735,984 | — | — |
| Feb 12, 2024 | Westlake BioPartners GP I, LLC 10% owner | Derivative conversion | +735,984 | — | — |
| Feb 12, 2024 | Bain Capital Life Sciences Fund III, L.P. 10% owner | Open-market purchase | +450,000 | $22.00 | $9,900,000 |
| Feb 12, 2024 | GILEAD SCIENCES, INC. 10% owner | Open-market purchase | +910,000 | $22.00 | $20,020,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.